Aishwarya Saxena

Panacea Biotec

Panacea Biotec is a research-based health management company involved in research, manufacturing and marketing of high-quality, affordable pharmaceutical, vaccines and herbal products. The product portfolio includes highly innovative prescription products in important therapeutic areas like pain management, diabetes, cardiovascular, renal disease management, osteoporosis, gastro-intestinal care products and vaccines. Panacea Biotec is committed towards disease prevention by introducing Innovative Vaccines that helps to reduce child mortality. Our portfolio consists of worlds first fully liquid Hexavalent vaccine i.e. EasySix (DTwP-Hib-HepB-IPV), the world's first fully-liquid Pentavalent vaccine i.e. Easyfive-TT (DTwP-Hib-HepB), Oral Polio vaccines (like bOPV, tOPV, mOPV), etc. We have a high-impact pipeline of vaccines including Pneumococcal conjugate vaccines (PCV), tetravalent dengue vaccine, etc. We have supplied 10+ billion immunizations of Polio vaccines in last 20 years, 150+ million immunizations of Novel Innovative fully liquid wP-based vaccines like the wP-Hexavalent vaccine (DTwP-Hib-HepB-IPV). And are a trusted partner for WHO, GAVI and UN Agencies with track-record of sustainable supplies for UNICEF, PAHO, and National Immunization Programs. In Pharmaceuticals, we have discovered and commercialised a NCE, Sitcom – that helps in Haemorrhoids and Piles. It is the leading brand in its segment in India and many other countries. We also have built leading brands like Pangraf, Mycept, Glizid, Livoluk, and PacliAll across transplantation, diabetes, constipation, and oncology. Our facilities are WHO Prequalified, US FDA approved and cGMP compliant. Our products are available across more than 145 countries including US, Germany, among other markets.